Use of HPV testing for cervical screening in vaccinated women-Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study

HPV immunisation and cervical screening—confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study

(2016) T J Palmer et al.   BRITISH JOURNAL OF CANCER

In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: Implications for post-vaccine surveillance studies

(2015) Alyssa M. Cornall et al.   JOURNAL OF VIROLOGICAL METHODS

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

(2015) Mélanie Drolet et al.   LANCET INFECTIOUS DISEASES

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

(2014) K G J Pollock et al.   BRITISH JOURNAL OF CANCER

Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology

(2014) Louise T. Thomsen et al.   INTERNATIONAL JOURNAL OF CANCER

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

(2014) Sepehr N Tabrizi et al.   LANCET INFECTIOUS DISEASES

Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact

(2013) Kimberley Kavanagh et al.   BMC INFECTIOUS DISEASES

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

(2013) Guglielmo Ronco et al.   LANCET

Aggregation and Competitive Exclusion: Explaining the Coexistence of Human Papillomavirus Types and the Effectiveness of Limited Vaccine Conferred Cross-Immunity

(2012) E. K. Waters   ACTA BIOTHEORETICA

Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)

(2012) Joseph Monsonego et al.   GYNECOLOGIC ONCOLOGY

The APTIMA HPV assayversusthe hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy

(2012) Marc Arbyn et al.   INTERNATIONAL JOURNAL OF CANCER

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

(2012) J. A. Kahn et al.   PEDIATRICS

Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical model

(2012) Yoon Hong Choi et al.   VACCINE

HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland

(2011) M C O'Leary et al.   BRITISH JOURNAL OF CANCER

Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers

(2011) Seiichiro Mori et al.   CANCER SCIENCE

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening

(2011) Dorien C. Rijkaart et al.   INTERNATIONAL JOURNAL OF CANCER